Recently, it was suggested that the IM resistance in CML cells should be handled through the combined treatment of BCR–ABL kinase inhibitor with histone deacetylase (HDAC) inhibitors.4–6. This evidence concerns the gene HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive.